Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;126(7):989-997.
doi: 10.1007/s11547-021-01352-w. Epub 2021 Apr 9.

Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes

Rosario Mazzola  1 , Francesco Cuccia  2 , Vanessa Figlia  1 , Michele Rigo  1 , Luca Nicosia  1 , Niccolò Giaj-Levra  1 , Francesco Ricchetti  1 , Claudio Vitale  1 , Beatrice Mantoan  1 , Gioacchino Di Paola  3 , Antonio De Simone  1 , Davide Gurrera  1 , Gianluisa Sicignano  1 , Stefania Naccarato  1 , Ruggero Ruggieri  1 , Filippo Alongi  1   4
Affiliations

Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes

Rosario Mazzola et al. Radiol Med. 2021 Jul.

Abstract

Objectives: To report preliminary data on feasibility and patient-reported outcomes following PSMA-PET/CT guided SBRT by means of 1.5 T MRI-Linac.

Methods and materials: Between October 2019 and April 2020, twenty consecutive castration sensitive oligorecurrent prostate cancer patients were enrolled in an ethical committee approved prospective observational study (Protocol n. XXXX) and treated with PSMA-PET/CT guided SBRT by means of 1.5 T MRI-Linac (Unity, Elekta AB, Stockholm, Sweden). The mean delivered dose was 35 Gy in 5 fractions. Clinicians reported toxicity was prospectively collected according to Common Terminology Criteria for Adverse Events v5.0. Quality of life (QoL) assessment was performed using EORTC-QLQ C30 questionnaires administered at baseline, end of treatment and at first follow-up.

Results: Twenty-five lesions in 20 castration sensitive oligorecurrent patients were treated: the most commonly treated anatomic sites were nodal (n = 16) and pelvic bone (n = 9). Median PSA-value preMRI guided SBRT was 1.16 ng/mL (range, 0.27-8.9), whereas median PSA value at first follow-up after SBRT was 0.44 ng/mL (range, 0.06-8.15). At first follow-up, for 16 patients showing detectable PSA, PSMA-PET/CT was performed detecting, respectively, in 6 cases partial response and in 10 cases complete response. In the remaining cases, PSA-value was undetectable after SBRT. Radiotherapy treatment was safe and well tolerated according to the PROMs. No acute G2 or higher toxicities were recorded.

Conclusions: The current series represent the largest one exploring the feasibility and patient-reported outcomes following PSMA-PET/CT guided SBRT by means of 1.5 T MRI-Linac. The preliminary findings here reported are encouraging in terms of effectiveness and tolerability.

Keywords: MRI-Linac; Oligometastases; Prostate cancer; Radiotherapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fossati N, Gandaglia G, Briganti A, Montorsi F (2019) The emerging role of PET-CT scan after radical prostatectomy: still a long way to go. Lancet Oncol 20(9):1193–1195. https://doi.org/10.1016/S1470-2045(19)30501-7 - DOI - PubMed
    1. EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2
    1. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms [Internet]. Available: https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ . Accessed 9 May 2018
    1. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C et al (2019) (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol 20(9):1286–1294. https://doi.org/10.1016/S1470-2045(19)30415-2 - DOI - PubMed - PMC
    1. Mazzola R, Cuccia F, Figlia V, Giaj-Levra N, Nicosia L, Ricchetti F et al (2019) New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: Is the era of melting glaciers upcoming? Transl Androl Urol 8(Suppl 5):S538–S541. https://doi.org/10.21037/tau.2019.12.34 - DOI - PubMed - PMC

LinkOut - more resources